Skip to content
PubMed This is a summary of 59 peer-reviewed journal articles Updated
Neurology

Choreoacanthocytosis (VPS13A disease): A Patient Guide

At a Glance

Choreoacanthocytosis, also called VPS13A disease, is a rare inherited neurological disorder caused by changes in both copies of the VPS13A gene. Genetic testing confirms the diagnosis, while coordinated care helps manage movement, swallowing, seizures, and behavior.

Choreoacanthocytosis, increasingly known as VPS13A disease, is an ultra-rare, inherited neurological condition that affects the way the brain controls movement and behavior [1]. It is a progressive disorder, meaning symptoms tend to change and develop over time as certain nerve cells in the brain are affected [2]. Because it is so rare, many families spend years searching for an answer before receiving a definitive diagnosis through genetic testing [3].

The condition is named for two of its most visible features: chorea—involuntary, irregular “dance-like” movements—and acanthocytosis, which refers to irregular, spiky red blood cells that can sometimes be seen under a microscope [4]. However, doctors now recognize that the condition involves much more than just these two signs. It often includes orolingual dyskinesia, which are forceful involuntary movements of the tongue and jaw that can lead to accidental biting of the lips and cheeks, as well as feeding dystonia, which makes swallowing food a significant challenge [2].

Beyond movement, the condition can affect many parts of the body and mind. Some people experience seizures, which may even be the first sign of the disease, while others may notice muscle weakness, a loss of sensation in the limbs, or changes in mood and personality [5][6]. Because the symptoms are so varied, a definitive diagnosis cannot rely on a blood smear alone; instead, it requires genetic testing to identify biallelic pathogenic or likely pathogenic variants in the VPS13A gene [7]. This gene is responsible for producing a protein called chorein, which helps maintain the health of cell membranes [8].

While there is currently no cure to stop the progression of VPS13A disease, there is a great deal that can be done to manage it. An integrated, multidisciplinary approach is the standard of care, bringing together neurologists, speech therapists, and other specialists to address each symptom [9]. From advanced options like Deep Brain Stimulation (DBS) for movement control at expert centers, to specialized dental guards and dietary adjustments for safer eating, these interventions are designed to protect your safety and improve your day-to-day quality of life [10][11]. Through careful management and a strong care team, patients and families can find ways to navigate the challenges of this rare condition.

Common questions in this guide

What is choreoacanthocytosis, or VPS13A disease?
It is an ultra-rare inherited neurological disorder that progressively affects movement, swallowing, seizures, behavior, and other nervous-system functions. It is caused by disease-causing variants in both copies of the VPS13A gene.
How is VPS13A disease diagnosed?
Diagnosis requires genetic testing that identifies disease-causing or likely disease-causing variants in both copies of VPS13A. A blood smear may show spiky red blood cells, but that finding alone cannot confirm the condition.
What symptoms can VPS13A disease cause?
Symptoms may include irregular involuntary movements, forceful tongue and jaw movements, trouble swallowing, seizures, muscle weakness, reduced sensation in the limbs, and changes in mood or personality. Symptoms vary and usually change over time as the condition progresses.
Is there a cure for VPS13A disease?
There is currently no cure that stops progression. Multidisciplinary care can manage symptoms and improve safety and quality of life, and Deep Brain Stimulation may help movement for some people at expert centers.
How can swallowing and aspiration risks be managed in VPS13A disease?
A speech therapist and nutrition professional can help assess swallowing and tailor food textures, eating strategies, and dietary adjustments. The care team should monitor for aspiration, which occurs when food or liquid enters the airway, and address safety needs as symptoms change.
Is VPS13A disease inherited, and should relatives have genetic counseling?
VPS13A disease follows an autosomal recessive inheritance pattern, meaning a person inherits disease-causing changes in both copies of the gene. A medical genetics team can explain family risks and whether relatives may benefit from testing.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Choreoacanthocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific VPS13A variants were identified in my report, and does the testing include copy-number analysis to look for large deletions?
  2. 2.How can we coordinate a multidisciplinary team including neurology, speech therapy, and nutrition to manage my symptoms?
  3. 3.What is the best way to monitor my risk for aspiration or seizures as the condition progresses?
  4. 4.Are there specific clinical trials or patient registries for VPS13A disease that I should consider joining?

References

References (11)
  1. 1

    Untangling the Thorns: Advances in the Neuroacanthocytosis Syndromes.

    Walker RH

    Journal of movement disorders 2015; (8(2)):41-54 doi:10.14802/jmd.15009.

    PMID: 26090076
  2. 2

    Clinical variability of neuroacanthocytosis syndromes-a series of six patients with long follow-up.

    Dulski J, Sołtan W, Schinwelski M, et al.

    Clinical neurology and neurosurgery 2016; (147()):78-83.

    PMID: 27310290
  3. 3

    Progressive ataxia and orolingual chorea revealing a novel VPS13A variant: a case report of chorea-acanthocytosis without peripheral acanthocytosis with a literature review.

    Ouskri A, Bouhda N, Khaissidi K, et al.

    Neurogenetics 2026; (27(1)).

    PMID: 42631781
  4. 4

    Neuropathy-predominant and hyperkinetic-dystonic presentations in two siblings with a homozygous VPS13A variant: long-term follow-up and family-based clinical analysis.

    Luo Y, Chen J, Ling T, et al.

    BMC neurology 2026; doi:10.1186/s12883-026-05170-3.

    PMID: 42426634
  5. 5

    The Diverse Neuromuscular Spectrum of VPS13A Disease.

    Buchberger A, Riedel E, Hackenberg M, et al.

    Annals of clinical and translational neurology 2026; (13(1)):157-169 doi:10.1002/acn3.70198.

    PMID: 41030128
  6. 6

    Novel pathogenic VPS13A gene mutations in Japanese patients with chorea-acanthocytosis.

    Nishida Y, Nakamura M, Urata Y, et al.

    Neurology. Genetics 2019; (5(3)):e332 doi:10.1212/NXG.0000000000000332.

    PMID: 31192303
  7. 7

    Identification of two compound heterozygous VPS13A large deletions in chorea-acanthocytosis only by protein and quantitative DNA analysis.

    Spieler D, Velayos-Baeza A, Mühlbäck A, et al.

    Molecular genetics & genomic medicine 2020; (8(9)):e1179 doi:10.1002/mgg3.1179.

    PMID: 32056394
  8. 8

    VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites.

    Kumar N, Leonzino M, Hancock-Cerutti W, et al.

    The Journal of cell biology 2018; (217(10)):3625-3639 doi:10.1083/jcb.201807019.

    PMID: 30093493
  9. 9

    Management of Neuroacanthocytosis Syndromes.

    Walker RH

    Tremor and other hyperkinetic movements (New York, N.Y.) 2015; (5()):346 doi:10.7916/D8W66K48.

    PMID: 26504667
  10. 10

    Two case reports of chorea-acanthocytosis and review of literature.

    Huang S, Zhang J, Tao M, et al.

    European journal of medical research 2022; (27(1)):22 doi:10.1186/s40001-022-00646-7.

    PMID: 35130982
  11. 11

    Deep brain stimulation for chorea-acanthocytosis: a systematic review.

    Wu Y, Xu YY, Gao Y, et al.

    Neurosurgical review 2022; (45(3)):1861-1871 doi:10.1007/s10143-022-01735-1.

    PMID: 35020105

This page provides general information about choreoacanthocytosis (VPS13A disease) and is not medical advice. A neurology and medical genetics team can help interpret test results and plan care for your situation.